Source:http://linkedlifedata.com/resource/pubmed/id/14551502
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2003-10-10
|
pubmed:abstractText |
Dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in 5-fluorouracil (5-FU) catabolism, has been a key target for the development of novel oral fluoropyrimidines. DPD-inhibiting oral fluoropyrimidines showing promise in early clinical studies included UFT (the 5-FU prodrug, tegafur, plus the DPD substrate, uracil), eniluracil (an irreversible DPD inhibitor that improves the oral bioavailability of 5-FU) and S-1 (tegafur plus a reversible DPD inhibitor, 5-chloro-2,4-dihydroxypyridine, and oxonic acid). However, results from phase II/III trials evaluating these agents as first-line therapy for metastatic colorectal cancer have been disappointing. Although DPD-inhibiting oral fluoropyrimidines have some activity in colorectal cancer and oral administration provides significant convenience advantages, the inferior efficacy of UFT/leucovorin and eniluracil/5-FU versus 5-FU/leucovorin in phase III trials does not support the use of these compounds. A feasible regimen for the phase III development of S-1 outside Japan has not been defined. Thus the DPD-inhibiting oral fluoropyrimidines have failed to fulfill their early promise: clinical data indicate that none of these compounds is likely to improve outcomes for patients with metastatic colorectal cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Dihydrouracil Dehydrogenase (NADP),
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0959-4973
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
695-702
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:14551502-Administration, Oral,
pubmed-meshheading:14551502-Antimetabolites, Antineoplastic,
pubmed-meshheading:14551502-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14551502-Clinical Trials, Phase II as Topic,
pubmed-meshheading:14551502-Clinical Trials, Phase III as Topic,
pubmed-meshheading:14551502-Colorectal Neoplasms,
pubmed-meshheading:14551502-Dihydrouracil Dehydrogenase (NADP),
pubmed-meshheading:14551502-Drug Combinations,
pubmed-meshheading:14551502-Fluorouracil,
pubmed-meshheading:14551502-Humans
|
pubmed:year |
2003
|
pubmed:articleTitle |
Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.
|
pubmed:affiliation |
Department of Internal Medicine, Martin Luther University Halle, Halle/Saale, Germany. hans-joachim.schmoll@medizin.uni-halle.de
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Review
|